@Greystone , The post you referred to was an answer from Dr Bradley Glover our new COO. He came over from Celularity to join IMU. So he was at Celularity working on allogenic CarT when IMU announced their collaboration with Celularity.
He would have had a very good understanding of CF33 and Allogenic CarT therapies from this previous work experience.
And yes it was post Azer-Cel when he joined IMU . So I took it that he was referring to CF33 and Azer-Cel.
Sorry to hear about your younger sister in law. Sadly a whole new dimension has been added to the scurge of cancer by the emergence of ‘turbo cancer’. That has appeared since the Covid Vaccines. There is a considerable and mounting body of evidence and research linking the Covid vaccines to this problem.
We have a friend who had been cleared of breast cancer , which suddenly roared back to life quite aggressively after keeping up with the govt mandated vaccine schedule.
If they are linked, and as aggressive as reports from oncologist suggest, maybe Oncarlytics will need to be fast tracked. Because reports suggest these ‘turbo’ cancers are very aggressive. Google Prof Dalgleish for more info.
It’s great to hear that you are still optimistic about the future for IMU.
